<DOC>
	<DOC>NCT00583596</DOC>
	<brief_summary>AGA-004 - The objective of the study is to determine safety, effectiveness and clinical utility of the AMPLATZER Duct Occluder in patients with patent ductus arteriosus. AGA-007 - The objective of this study is to evaluate the long term safety and effectiveness issues that may not have have been adequately addressed during AGA-004.</brief_summary>
	<brief_title>Closure Of Patent Ductus Arteriosus With the AMPLATZER Duct Occluder the AMPLATZER® Duct Occluder</brief_title>
	<detailed_description />
	<mesh_term>Ductus Arteriosus, Patent</mesh_term>
	<criteria>Patients with a demonstrated patent ductus arteriosus Body weight &gt; 5 Kilograms Pulmonary vascular resistance above 8 Woods units or a Rp/Rs &gt;0.4. Additional cardiac or noncardiac abnormality that can reasonably be expected to significantly affect the patient's health adversely in the next two years, i.e.: cancer, Eisenmenger's syndrome, other serious congenital heart disease. Pelvic vein or inferior vena cava thrombosis Sepsis (local/generalized) or any type of infection that cannot be successfully treated prior to device placement. History of repeated pulmonary infection Demonstrated intracardiac thrombi on echocardiography • Inability to obtain informed consent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>patent ductus arteriosus (PDA)</keyword>
</DOC>